Skip to main content

Table 3 Cox univariate and multivariate analyses demonstrating the influence of clinicopathological parameters and TP gene expression on time to progression

From: Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer

 

Univariate

Multivariate

 

HR

95% CI P*

HR

95% CI

P*

Gender

     

  Male

1

 

1

  

  Female

1.46

0.95-2.25 NS

1.48

0.94-2.34

NS

Age (years)

1.00

0.99-1.03 NS

1.01

0.98-1.04

NS

Tumour location

     

  Rectum

1

 

1

  

  Colon

1.49

0.96-2.34 NS

1.21

0.74-2.01

NS

Tumour differentiation

     

  Well/Medium

1

 

1

  

  Poor

1.65

1.03-2.61

1.50

0.92-2.42

 

  Mucinous

2.04

0.84-4.23 NS

2.12

0.83-4.78

NS

TP gene expression

     

  High

1

 

1

  

  Low

1.78

1.15-2.79 < 0.05

1.61

1.01-2.61

<0.05

ECOG performance status

     

  0

1

 

1

  

  1

1.09

0.62-1.81

1.18

0.67-1.98

 

  2-3

6.51

2.44-14.5 < 0.05

7.17

2.60-16.8

<0.05

Chemotherapy

     

  Combination treatment†

1

 

1

  

  Single treatment‡

1.29

0.78-2.07 NS

1.11

0.59-2.05

NS

  1. Abbreviation: HR Hazard Ratio, CI Confidence interval, TP Thymidine Phosphorylase, ECOG Eastern Cooperative Oncology Group *Statistical method; Cox proportional hazards regression. †5-fluorouracil or capecitabine in combination with oxaliplatin or irinotecan; ‡5-fluorouracil or capecitabine.
Back to article page

BMC Clinical Pathology

ISSN: 1472-6890

Contact us